Coronado Industries' Medical Director to Begin Study in Italy.Business/Technology Editors FOUNTAIN HILLS, Ariz.--(BUSINESS WIRE)--June 5, 2001 Coronado Industries, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: CDIK), a manufacturer of proprietary pneumatic devices for the effective treatment of glaucoma, announced that its Medical Director, Dr. Leo D. Bores, will travel to Italy on June 22, 2001, to commence a Novartis (NYSE NYSE See: New York Stock Exchange : NVS NVS - Non-Volatile Storage ) study on June 25, 2001 of the Company's Pneumatic Trabeculoplasty (TM) treatment system for glaucoma. The study is part of the due diligence required by an option agreement recently signed between Novartis and Coronado Industries for exclusive global licensing and distribution rights. All medical and regulatory ramifications ramifications npl → Auswirkungen pl of the study have been finalized. "Coronado and Novartis look forward to the start of the study, and to the continuation of our relationship as defined under our contract," noted Gary Smith, President of Coronado Industries, Inc. Coronado Industries, through its wholly-owned subsidiaries American Glaucoma and Ophthalmic International, focuses on the development and testing of a patented procedure, Pneumatic Trabeculoplasty (PNT PNT Point PNT Paint (MacPaint graphic file format) PNT Patient PNT Pentagon (Washington, DC; US DoD) PNT Positioning, Navigation and Timing PNT Prime Number Theorem PNT Phenytoin (TM)), a non-invasive, highly-effective, and low-cost alternative to traditional treatments. Currently, the Company is allowed to market its pneumatic suction device and treatment throughout the European marketplace under a CE Mark (allowing manufacturers to freely sell their products) from the European Commission. Pending FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval, the Company will license its patented treatment procedure and equipment in the United States. Corporate Contact: Richard Smith, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , 480/837-6810; Investor Relations Contact: OTC Financial Network, Rick McCaffrey, 800/375-4678, ext. 621, rick@otcfn.com; Media Relations Contact: Silvana Rodriguez, 561/750-9800 x 21; E-mail: srodriguez@transmediagroup.com For additional information, see www.coronadoindustries.com or www.otcfn.com/cdik/4pg.html Forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion